Catalyst Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary

Catalyst Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Performance and Operational Drivers Achieved record 2025 revenues of $589 million, driven by 20.3% growth in net product revenue through enhanced patient identification and market penetration. FIRDAPSE growth was propelled by a 40% increase in identified patient leads and a 12% reduction in early discontinuations following a new pharmacy outreach program. AGAMREE's successful first full year on the market reached 100% pene ...